• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Rezolute Inc.

    3/7/25 9:59:15 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RZLT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    REZOLUTE INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    76200L309

    (CUSIP Number)


    02/28/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    76200L309


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,360,907.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,360,907.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,360,907.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.5 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    76200L309


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,360,907.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,360,907.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.5 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    REZOLUTE INC
    (b)Address of issuer's principal executive offices:

    275 SHORELINE DRIVE,SUITE 500,REDWOOD CITY,CA,US,94065
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    76200L309
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6360907.00
    (b)Percent of class:

    10.5  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    6360907.00

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of REZOLUTE INC. No one other person's interest in the COMMON STOCK of REZOLUTE INC is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:03/06/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:03/06/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003.** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $RZLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RZLT

    DatePrice TargetRatingAnalyst
    11/5/2024$12.00Outperform
    Wedbush
    8/27/2024$11.00Buy
    Guggenheim
    7/17/2024$13.00Buy
    BTIG Research
    6/4/2024$14.00Buy
    Craig Hallum
    4/9/2024$8.00Buy
    Maxim Group
    8/2/2022$17.00Buy
    Canaccord Genuity
    6/15/2022$9.00Overweight
    Cantor Fitzgerald
    11/29/2021$30.00 → $17.00Buy
    Canaccord Genuity
    More analyst ratings

    $RZLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

      Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by HI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI.  BTD for ersodetug was granted based on clinical trial data across the overall program and a re

      5/5/25 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute to Participate in Upcoming Investor Conferences

      REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences: Event: The Citizens JMP Life Sciences Conference Date: May 7-8, 2025 Event: H.C. Wainwright BioConnect Investor Conference Date: May 20, 2025 Event: Craig-Hallum Institutional Investor Conference Date: May 28, 2025 Event: Jefferies Global Healthcare Conference Date: June 3-5, 2025 Management will be participating in one-on-one investor meetings thro

      5/1/25 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute, Inc. Announces Closing of Underwritten Offering

      NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its previously announced underwritten offering (the "Offering") of an aggregate of 24,940,769 shares of its common stock at an offering price of $3.25 per share, which includes 4,153,846 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 6,905,385 shares of common stock a

      4/25/25 4:30:35 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Financials

    Live finance-specific insights

    See more
    • Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

      Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and potential to move into late-stage clinical development to further evaluate RZ358 in this population REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial re

      2/13/24 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Reports First Quarter Fiscal 2024 Results

      REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023. "We are on track to commence our Phase 3 study for RZ358 to treat congenital hyperinsulinism prior to year-end and are delighted to have recently obtained PRIME eligibility from the European Medicines Agency for this indication," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "We also anticipate completing enrollment this quarter for our o

      11/13/23 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

      REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2023. "We are delighted that we are poised to initiate sunRIZE – our Phase 3 study of RZ358, which we hope will bring us one step closer to making this therapy available to patients and their families suffering from congenital hyperinsulinism. We are also anticipating results from our Phase 2 study of RZ402 in the first quarter of 20

      9/14/23 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hogenhuis Wladimir bought $19,733 worth of shares (6,758 units at $2.92), increasing direct ownership by 9% to 84,025 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      4/1/25 3:52:55 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Elam Nevan C bought $34,999 worth of shares (12,302 units at $2.85), increasing direct ownership by 6% to 224,119 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/31/25 9:18:52 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Evans Daron bought $57,700 worth of shares (20,000 units at $2.88), increasing direct ownership by 4% to 237,900 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/28/25 8:40:13 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RZLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $RZLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RZLT
    SEC Filings

    See more
    • Director Hogenhuis Wladimir bought $19,733 worth of shares (6,758 units at $2.92), increasing direct ownership by 9% to 84,025 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      4/1/25 3:52:55 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Elam Nevan C bought $34,999 worth of shares (12,302 units at $2.85), increasing direct ownership by 6% to 224,119 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/31/25 9:18:52 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Evans Daron bought $57,700 worth of shares (20,000 units at $2.88), increasing direct ownership by 4% to 237,900 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/28/25 8:40:13 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/14/24 6:59:50 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/14/24 10:04:23 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/13/24 5:31:40 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Rezolute with a new price target

      Wedbush initiated coverage of Rezolute with a rating of Outperform and set a new price target of $12.00

      11/5/24 6:25:51 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Rezolute with a new price target

      Guggenheim initiated coverage of Rezolute with a rating of Buy and set a new price target of $11.00

      8/27/24 7:36:43 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Rezolute with a new price target

      BTIG Research initiated coverage of Rezolute with a rating of Buy and set a new price target of $13.00

      7/17/24 7:55:53 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Rezolute, Inc. (0001509261) (Filer)

      4/28/25 5:00:44 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Rezolute, Inc. (0001509261) (Filer)

      4/23/25 5:22:25 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Rezolute Inc.

      424B5 - Rezolute, Inc. (0001509261) (Filer)

      4/23/25 5:20:21 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

      REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. "We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for p

      3/26/25 7:30:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

      REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement for his appointment (the "Inducement Grant"). About Mr. Evans "This is a pivotal year for Rezolute as we initiated our Phase 3 clinical study for RZ358 in congenital hyperinsulinism and anticipate reporting topline data from our Phase 2 study for RZ402 in diabetic macular edema in the secon

      1/24/24 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute's Oral PKI for Treatment of DME

      REDWOOD CITY, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that the Company has initiated dosing in a Phase 1b multiple-ascending dose study of RZ402, Rezolute's investigational oral plasma kallikrein inhibitor (PKI) for the treatment of diabetic macular edema (DME). Rezolute also announced the appointment of ophthalmology expert and key opinion leader, Dr. Rajat Agrawal, MD, MS, as Vice President, Clinical Development to lead the RZ402 clinical development program. "The Phase 1b study will evaluate the

      8/10/21 7:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care